Metastatic Penile Squamous Cell Carcinoma

1

Review clinical trials related to Metastatic Penile Squamous Cell Carcinoma. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Enfortumab Vedotin for the Treatment of Patients With Metastatic or Unresectable Squamous Cell Carcinoma of the Penis

This phase II trial tests how well enfortumab vedotin works for treating patients with squamous cell carcinoma of the penis that has spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable). Enfortumab vedotin is a monoclonal antibody, enfortumab, linked to an anticancer drug called vedotin. It works by helping the immune system to slow or stop the growth of tumor cells. Enfortumab attaches to a protein called nectin-4 on tumor cells in a targeted way and delivers vedotin to kill them.

Participants needed: 28
Trial details
Phase: Phase 2Age: 18+Biological sex: MaleType: InterventionalSponsor: Mayo ClinicUpdated: Jun 8, 2026Locations: 3
Eligibility criteria

Age ≥ 18 years [+19]

Pure verrucous carcinoma of the penis [+27]